嘉应制药股价微跌1.44%，签约多款创新药项目加速布局

Core Viewpoint - The stock price of Jiaying Pharmaceutical is reported at 6.86 yuan, reflecting a decrease of 0.10 yuan or 1.44% from the previous trading day, with a trading volume of 0.62 billion yuan [1] Company Overview - Jiaying Pharmaceutical operates in the traditional Chinese medicine sector, focusing on the research, development, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company has been advancing a dual-driven strategy of "traditional Chinese medicine characteristics + chemical drug innovation," enhancing its product matrix layout [1] Recent Developments - Jiaying Pharmaceutical has recently signed research and development cooperation agreements with multiple institutions, involving antihistamine drug Bilastine tablets and high-end generic drug projects JH002, JH003, and JH004 [1] - Bilastine is primarily used for the treatment of allergic rhinitis and urticaria, while JH003 and JH004 target hyperuricemia/gout and heart failure, respectively, further enriching the company's product line [1] Financial Insights - On the funding side, Jiaying Pharmaceutical experienced a net outflow of 2.5078 million yuan in main funds today, while the net inflow over the past five days was 7.7439 million yuan [1]